×

A New Watchlist

We’ve updated Watchlist! The changes include a new, responsive design featuring extended-hours data and more news. Learn more.
ALXNUS
Open
Back To Top
Last Updated: Sep 23, 2019 3:39 p.m. EDT Real time quote

$104.89

-1.43 -1.34%
Health Care/Life Sciences 0.45%
Previous Close
$106.32
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
42.15% vs Avg.
Volume: 996.5K 65 Day Avg. - 2.4M
Open: 106.39
Last: 104.89
104.87 Day Low/High 107.00
Day Range
92.56 52 Week Low/High 141.86

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $106.39
  • Day Range 104.87 - 107.00
  • 52 Week Range 92.56 - 141.86
  • Market Cap $23.84B
  • Shares Outstanding 224.23M
  • Public Float 223.53M
  • Beta 1.41
  • Rev. per Employee $1.56M
  • P/E Ratio 17.82
  • EPS $5.92
  • Yield n/a
  • Dividend n/a
  • Ex-Dividend Date n/a
  • Short Interest 3.48M 08/30/19
  • % of Float Shorted 1.56%
  • Average Volume 2.36M

Performance

5 Day
  • -3.36%
1 Month
  • -6.06%
3 Month
  • -17.40%
YTD
  • 7.73%
1 Year
  • -18.38%

Recent News

  • MarketWatch
  • WSJ
Barron's

The Dow Is Down as Investors Wait for the Federal Reserve

Investors are waiting to see if the Federal Reserve will lower interest rates again.

Barron's

Alexion CFO Is Unexpectedly Leaving

Alexion Pharmaceutical CFO Paul Clancy is unexpectedly leaving the company after two years, and analysts are registering surprise but little concern.

Barron's

Alexion Loses in Patent Push, but Stock Doesn’t Stumble

The European Patent Office didn’t accept an Alexion effort to extend its patent on its blockbuster drug Soliris, which means the treatment will likely face biosimilar competition in the key European market as early as 2022.

Barron's

The Dow Is Down 345 Points Because U.S. Manufacturing Is Weak

The three major U.S. stock indexes fell as data from August showed that U.S. manufacturing activity slowed for the first time in three years. Also, China lodged an official complaint with the World Trade Organization over U.S. tariffs, and the Brexit process continued to be tumultuous.

Alexion Pharmaceuticals stock price target cut to $157 from $172 at SVB Leerink

Barron's

The Dow Is Flat Because China Trade Tensions Take a Time Out

The three major U.S. stock market indexes were near flat as investors embraced an apparent drop in U.S.-China trade tensions.

Alexion Pharmaceuticals maintained as buy at CFRA

Barron's

Bristol-Meyers Deal for Celgene Moves Ahead

Biotech company Amgen said Monday it would buy the rights to the psoriasis drug Otezla from Celgene for $13.4 billion. That will allow Bristol-Myers Squibb to move forward with its merger with Celgene.

Barron's

Alexion Stock Is Slipping Because an Amgen Bid Looks Less Likely

Rumors of an imminent acquisition of Alexion Pharmaceuticals sent the stock jumping, and while a that may not pan out, SVB Leerink thinks a more-concrete deal may be in the drug maker’s future.

Read full story

20 companies, including Amazon and Chipotle, that are getting more profitable as sales improve

Barron's

Alexion Investors Can’t Catch a Break. Earnings Beat Forecasts, but the Stock Is Falling

Analyst are positive about the pharmaceutical stock, but investors appear to be wary.

Read full story

Health care is one of the stock market’s healthiest sectors right now

Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing

Shares of health companies were down Monday, with both the Health Care Select Sector SPDR Fund ETF and the SPDR S&P Pharmaceuticals ETF falling 0.6% in morning intraday trade. Shares of Cardinal Health Inc. led the losers in the S&P 500's health-care ETF, falling 3.1% after the company said CFO Jorge Gomez would leaving the company, followed by declines in shares of Incyte Corp , Alexion Pharmaceuticals Inc. , and Biogen Inc. , Regeneron Pharmaceuticals Inc. and Amgen Inc. . The dip in health-care stocks comes after President Trump's announcement Friday that he was planning to soon issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries. "Our guess is drug stocks may be initially pressured this week," Jefferies health-care trading desk strategist Jared Holz wrote in an email to clients on Sunday evening. However, "feedback already suggests investors believe the executive order, if it comes to pass, will only be relevant for a handful of drugs (those that are very significant in revenue and administered in a physician's office)... at least at the onset," he wrote. The drop in health shares comes amid a broader decline in U.S. stocks, as investors grapple with doubts about whether the Federal Reserve will still cut interest rates after a strong U.S. jobs report Friday. The S&P 500 was down 0.4% Monday morning. The index has gained 18.8% in the year to date.

Barron's

Qualcomm Stock Falls as Dow Futures Point to Lower Open

U.S. stocks were poised to open lower on Friday, after staying closed Thursday for the Fourth of July.

Barron's

U.S. Gets Hundreds of Millions From Big Pharma in Medicare Co-Pay Settlements

Read full story
Barron's

The Dow Jones Industrial Average Fell as the Trade War Hurts Oil Prices

Read full story

Apple and 9 other stocks that tend to heat up in the summer

Barron's

Buy Gilead Stock as Biotech Returns to ‘Stability and Growth’

Alexion Pharmaceuticals started at outperform with $173 stock price target at Wedbush

Read full story

You can find plenty of solid stock bargains in this year’s worst-performing sector, analysts say

Stocks to Watch: Genesco, Lululemon, DocuSign, PagerDuty, and Medallia

Genesco, Lululemon, DocuSign, PagerDuty, and Medallia are among Friday’s stocks to watch.

  • on The Wall Street Journal

Stocks to Watch: Alphabet, H&R Block, Conn’s, and More

Alphabet, H&R Block, and Alexion Pharmaceuticals are among Tuesday’s stocks to watch, following the holiday weekend.

  • on The Wall Street Journal

Stocks to Watch: UPS, Caterpillar, Sprint, Chipotle, and More

United Parcel Service, Caterpillar, Tupperware Brands, Snap, Visa, and Chipotle are some of the companies with shares expected to trade actively on Wednesday.

  • on The Wall Street Journal

Stocks to Watch: Tesla, Symantec, Alexion Pharmaceuticals, Nordstrom

Some of the companies with shares expected to trade actively in today’s session include Tesla, which reported a new record for car deliveries, and EOG Resources, whose shares slid on fears of soft oil demand and excess supply.

  • on The Wall Street Journal
Read full story

A Connecticut Tax Story

  • on The Wall Street Journal
Read full story

Three Drug Companies to Pay $122.6 Million to Resolve Kickback Allegations

  • on The Wall Street Journal
Read full story

Stocks to Watch: Ford, Goldman, Spotify, Symantec, Papa John’s, Sysco, Clorox, Anadarko

  • on The Wall Street Journal
Read full story

Ned Lamont Touts Business Savvy in Run for Connecticut Governor

  • on The Wall Street Journal
Read full story

Connecticut Voters Wonder Who’ll Stop the Rain

  • on The Wall Street Journal
Read full story

U.S. Stocks End Lower After Fed Rate Increase

  • on The Wall Street Journal
Read full story

Nielsen Hires Former Honeywell Finance Chief

  • on The Wall Street Journal
Read full story

What Is Ailing the Drug Industry?

  • on The Wall Street Journal
Read full story

How Big Biotech Can Win Back Investors

  • on The Wall Street Journal
Read full story

Stocks to Watch: Amazon, Boeing, Mattel, Sears, Dollar General, ADT, Alexion, Williams-Sonoma

  • on The Wall Street Journal
Read full story

Stocks to Watch: AMD, Southwest Airlines, IBM, Alexion, Oracle, Scana, Sangamo Therapeutics

  • on The Wall Street Journal
Read full story

Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat

  • on The Wall Street Journal
Read full story

Connecticut, Already Strapped, Is Coming Up Short Again

  • on The Wall Street Journal
Read full story

Stocks to Watch: Amazon, Caterpillar, Alexion, 3M, United Continental, American Outdoor

  • on The Wall Street Journal
Read full story

Connecticut’s Housing Market Lags Behind Neighbor States

  • on The Wall Street Journal
Read full story

Today’s Top Supply Chain and Logistics News From WSJ

  • on The Wall Street Journal

Recent News

  • Other News
  • Press Releases

3 Reasons Growth Investors Will Love Alexion (ALXN)

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

  • on Zacks.com

3 Big Biotech Stocks Worth Adding to Your Portfolio Now

We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.

  • on Zacks.com

Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

  • on Zacks.com

Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

  • on Zacks.com

Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

  • on Zacks.com

7 Biotechs With Catalysts in the Next Month

Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.

  • on 247WallSt.com

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

  • on Zacks.com

ALXN or CBM: Which Is the Better Value Stock Right Now?

ALXN vs. CBM: Which Stock Is the Better Value Option?

  • on Zacks.com

New coverage - healthcare

New coverage - healthcare

  • on Seeking Alpha

Major Biotechs Scare Off Short Sellers

The August 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.

  • on 247WallSt.com

Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • on Zacks.com

Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus

Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.

  • on Zacks.com

Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.

  • on Zacks.com

Viela Bio IPO: At Phase 3 Of Development With Positive Results

Viela Bio IPO: At Phase 3 Of Development With Positive Results

  • on Seeking Alpha

10 Healthcare Stocks to Buy Despite the Headlines

10 Healthcare Stocks to Buy Despite the Headlines

  • on InvestorPlace.com

Credit Suisse Sticks to Its Buy Rating for Alexion Pharmaceuticals (ALXN)

Credit Suisse analyst Martin Auster maintained a Buy rating on Alexion Pharmaceuticals (ALXN) on September 5 and set a price target of $146. ...[...]

  • on SmarterAnalyst

Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.

  • on Zacks.com

Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?

Is (ALXN) Outperforming Other Medical Stocks This Year?

  • on Zacks.com

Alexion inks deal for ATTR investigational medicine in Japan

Alexion inks deal for ATTR investigational medicine in Japan

  • on Seeking Alpha

Apple, IPOs And German Auto (Stocks To Watch Podcast)

Apple, IPOs And German Auto (Stocks To Watch Podcast)

  • on Seeking Alpha

Blockbuster Drugs Market 2019 Global Technology, Development, Trends and Forecasts to 2025

Blockbuster Drugs Market 2019 Global Technology, Development, Trends and Forecasts to 2025

  • on Heraldkeepers

Global Enzyme Replacement Therapy Market by Global Business Players: Sanofi, Shire, BioMarin, AbbVie, Alexion, Allergan and more...

Global Enzyme Replacement Therapy Market by Global Business Players: Sanofi, Shire, BioMarin, AbbVie, Alexion, Allergan and more...

  • on Heraldkeepers

Nasdaq 100 Movers: ADBE, KLAC

Nasdaq 100 Movers: ADBE, KLAC

  • on MarketNewsVideo.com

Alexion Announces CFO Succession

Alexion Announces CFO Succession

  • on BusinessWire - BZX

Myasthenia Gravis Disease Market is anticipated to exceed USD 2,538.6 Million by 2026 – Leading Players like Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring etc.

Myasthenia Gravis Disease Market is anticipated to exceed USD 2,538.6 Million by 2026 – Leading Players like Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring etc.

  • on AmericaNewsHour

Alexion Partners With PluSport for Second Year

Alexion Partners With PluSport for Second Year

  • on 3BL Media

Rare Disease Drug SalesMarket 2018 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

Rare Disease Drug SalesMarket 2018 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

  • on Garth Media

Nasdaq 100 Movers: MELI, ALXN

Nasdaq 100 Movers: MELI, ALXN

  • on MarketNewsVideo.com

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

  • on BusinessWire - BZX

S&P 500 Movers: XEC, DRI

S&P 500 Movers: XEC, DRI

  • on MarketNewsVideo.com

Fortress Biotech to Present at September 2019 Investor Conferences

Fortress Biotech to Present at September 2019 Investor Conferences

  • on GlobeNewswire

Wave Life Sciences Expands Board of Directors with Three New Appointments

Wave Life Sciences Expands Board of Directors with Three New Appointments

  • on GlobeNewswire

Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

  • on BusinessWire - BZX

Nasdaq 100 Movers: WYNN, LRCX

Nasdaq 100 Movers: WYNN, LRCX

  • on MarketNewsVideo.com

Orphan Drugs Industry 2019 Global Market Growth, Size, Demand, Trends, Insights and Forecast 2025

Orphan Drugs Industry 2019 Global Market Growth, Size, Demand, Trends, Insights and Forecast 2025

  • on The Express Wire

Atypical Hemolytic Uremic Syndrome Drug Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2022

Atypical Hemolytic Uremic Syndrome Drug Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2022

  • on Garth Media

Nasdaq 100 Movers: ULTA, TSLA

Nasdaq 100 Movers: ULTA, TSLA

  • on MarketNewsVideo.com

Monoclonal Mouse Antibody Market Insights, Forecast to Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

Monoclonal Mouse Antibody Market Insights, Forecast to Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

  • on Garth Media

Orphan Drugs Market 2019 - Globally Market Size, Share, Analysis, Research, Business Growth and Forecast to 2023 | Industry Research Co

Orphan Drugs Market 2019 - Globally Market Size, Share, Analysis, Research, Business Growth and Forecast to 2023 | Industry Research Co

  • on The Express Wire

Global Mucopolysaccharidosis II Market 2019: Alexion Pharmaceuticals Inc, AngioChem Inc, ArmaGen Inc

Global Mucopolysaccharidosis II Market 2019: Alexion Pharmaceuticals Inc, AngioChem Inc, ArmaGen Inc

  • on Eon Market Research

Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. (See Full Profile)

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20 Full Ratings

Competitors

Name Chg % Market Cap
Ionis Pharmaceuticals Inc. -3.05% $8.81B
Biogen Inc. 0.73% $44.04B
Vertex Pharmaceuticals Inc. -1.20% $45.78B
Agios Pharmaceuticals Inc. 0.58% $2.13B
Regeneron Pharmaceuticals Inc. -0.32% $32.51B
Competitor Data Provided ByCapital Cube Logo